GeneDx Holdings Corp [WGS] stock is trading at $95.83, down -5.66%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The WGS shares have gain 22.86% over the last week, with a monthly amount glided 26.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
GeneDx Holdings Corp [NASDAQ: WGS] stock has seen the most recent analyst activity on August 28, 2024, when Wells Fargo initiated its Equal Weight rating and assigned the stock a price target of $34. Previously, Craig Hallum started tracking the stock with Buy rating on July 10, 2024, and set its price target to $43.
GeneDx Holdings Corp [WGS] stock has fluctuated between $4.61 and $115.60 over the past year. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. GeneDx Holdings Corp [NASDAQ: WGS] shares were valued at $95.83 at the most recent close of the market. An investor can expect a potential drop of -45.74% based on the average WGS price forecast.
Analyzing the WGS fundamentals
GeneDx Holdings Corp [NASDAQ:WGS] reported sales of 305.45M for the trailing twelve months, which represents a growth of 66.57%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.17%, and Net Profit Margin reading is -0.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.25 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 89.54 points at the first support level, and at 83.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 102.84, and for the 2nd resistance point, it is at 109.85.
Ratios To Look Out For
For context, GeneDx Holdings Corp’s Current Ratio is 3.61. Also, the Quick Ratio is 3.42, while the Cash Ratio stands at 1.55. Considering the valuation of this stock, the price to sales ratio is 8.81, the price to book ratio is 10.95.
Transactions by insiders
Recent insider trading involved Feeley Kevin, CHIEF FINANCIAL OFFICER, that happened on Jan 29 ’25 when 275.0 shares were sold. Chief Executive Officer, Stueland Katherine completed a deal on Jan 29 ’25 to sell 1657.0 shares. Meanwhile, Stockholder ICAHN SCHOOL OF MEDICINE AT MO bought 1.35 million shares on Jan 30 ’25.
